ALFA Filings
Every announcement, straight from the exchange
Every Glenmark Pharmaceuticals other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements with these filters
Glenmark Pharmaceuticals has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI Regulation 31(1)(b).
Glenmark Pharmaceuticals released its Business Responsibility & Sustainability Report for the financial year 2025-26. This filing adheres to SEBI's regulatory disclosure requirements.
Glenmark Pharmaceuticals updated its list of key officials authorized to determine event materiality and manage stock exchange disclosures under Regulation 30(5) of SEBI LODR.
Glenmark's subsidiary announced ISB 2301, a first-in-class multispecific activator targeting solid tumors. Clinical studies are planned for 2027 following IND submission later this year.